CD8A and cancer: Therefore, further exploration of T cell metabolism and its regulators, together with more specific elucidation of metabolic differences in CD8+ T cells in cancer patients responsive to ICI therapy, is essential for the consideration of immune cell metabolism as part of assessing the clinical efficacy of ICI therapy.